Vertex Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. 

CEO
Reshma Kewalramani
CEOReshma Kewalramani
Employees
6,100
Employees6,100
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1989
Founded1989
Employees
6,100
Employees6,100

VRTX Key Statistics

Market cap
118.07B
Market cap118.07B
Price-Earnings ratio
-118.10
Price-Earnings ratio-118.10
Dividend yield
Dividend yield
Average volume
1.01M
Average volume1.01M
High today
$469.96
High today$469.96
Low today
$458.14
Low today$458.14
Open price
$466.10
Open price$466.10
Volume
975.04K
Volume975.04K
52 Week high
$519.88
52 Week high$519.88
52 Week low
$377.85
52 Week low$377.85

VRTX News

TipRanks 2d
Cautious Hold Rating on Vertex Pharmaceuticals Amid Efficacy Uncertainty

Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Vertex Pharmaceuticals, retaining the price target of $460.00. Elevate Your Investing Strategy:...

Simply Wall St 3d
Vertex Pharmaceuticals Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment

experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimburs...

Vertex Pharmaceuticals Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment
Simply Wall St 4d
Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value

Over the last 7 days, the United States market has remained flat, yet it has experienced an 11% increase over the past year with earnings projected to grow by 1...

Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value

Analyst ratings

54%

of 35 ratings
Buy
54.3%
Hold
40%
Sell
5.7%

More VRTX News

TipRanks 5d
Vertex Pharmaceuticals price target raised to $517 from $515 at JPMorgan

JPMorgan raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $517 from $515 and keeps an Overweight rating on the shares. The firm adjusted the c...

People also own

Based on the portfolios of people who own VRTX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.